Researcher
Peter Hellings
- Disciplines:Dermatology
Affiliations
- Department of Head and Skin (Department)
Member
From1 Oct 2018 → Today - Department of Otorhinolaryngology (Department)
Member
From1 Oct 2015 → 30 Sep 2018
Publications
1 - 10 of 55
- Rapid and sustained effects of dupilumab in severe chronic rhinosinusitis with nasal polyps(2022)
Authors: Peter Hellings, Anju T Peters, Adam M Chaker, Enrico Heffler, Haixin Zhang, Amy Praestgaard, Scott Nash, Asif Hameed Khan, Shahid Siddiqui, Juby A Jacob-Nara, et al.
Pages: 958 - 962 - Dupilumab in CRSwNP : responder analysis using clinically meaningful efficacy outcome thresholds(2022)
Authors: ChienU+2010Chia Chuang, Isabelle Guillemin, Claus Bachert, Stella E. Lee, Peter Hellings, Wytske J. Fokkens, Nicolas Duverger, Chunpeng Fan, Nadia Daizadeh, Nikhil Amin, et al.
Pages: 259 - 264 - Estimating clinically meaningful change of efficacy outcomes in inadequately controlled chronic rhinosinusitis with nasal polyposis(2022)
Authors: Joseph K. Han, Claus Bachert, Stella E. Lee, Claire Hopkins, Enrico Heffler, Peter Hellings, Anju T. Peters, Siddhesh Kamat, Diane Whalley, Shanshan Qin, et al.
Pages: 265 - 271 - AROMA : real-world global registry of dupilumab for chronic rhinosinusitis with nasal polyps(2022)
Authors: Shahid Siddiqui, Claus Bachert, Adam M. Chaker, Joseph K. Han, Peter Hellings, Anju T. Peters, Enrico Heffler, Siddhesh Kamat, Haixin Zhang, Scott Nash, et al.
- Association between outdoor air pollution and chronic rhinosinusitis patient reported outcomes(2022)
Authors: S. Peeters, C. Wang, E. M. Bijnens, D. M. A. Bullens, W. J. Fokkens, Claus Bachert, Peter Hellings, T. S. Nawrot, S. F. Seys
- Rapid and sustained effects of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps : analysis of the SINUS-24 and SINUS-52 phase 3 trails(2021)Volume: 203
Authors: Peter Hellings, A Peters, AM Chaker, E Heffler, H Zhang, N Daizadeh, S Nash, Asif Hameed Khan, S Siddiqui, JA Jacob-Nara
Pages: A1345 - A1345 - Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma(2021)
Authors: Tanya M. Laidlaw, Claus Bachert, Nikhil Amin, Martin Desrosiers, Peter Hellings, Joaquim Mullol, Jorge F. Maspero, Mei Zhang, Xuezhou Mao, Asif H. Khan, et al.
Pages: 584 - 592.e1 - A 300 IR sublingual tablet is an effective, safe treatment for house dust mite induced allergic rhinitis : an international, double-blind, placebo-controlled, randomized phase III clinical trial(2021)
Authors: Pascal Demoly, Jonathan Corren, Peter Creticos, Frederic De Blay, Peter Hellings, Krzysztof Kowal, Martine Le Gall, Natalia Nenasheva, Giovanni Passalacqua, Oliver Pfaar, et al.
Pages: 1020 - 1030.e10 - Dupilumab reduces systemic corticosteroid use and sinonasal surgery rate in CRSwNP(2021)
Authors: M. Desrosiers, L.P. Mannent, N. Amin, G.W. Canonica, Peter Hellings, Philippe Gevaert, J. Mullol, S.E. Lee, S. Fujieda, J.K. Han, et al.
Pages: 301 - 311 - Health-related quality of life impairment among patients with severe chronic rhinosinusitis with nasal polyps in the SINUS-24 trial(2021)Volume: 147
Authors: Jorge Maspero, Carl Philpott, Peter Hellings, Claire Hopkins, Martin Wagenmann, Shahid Siddiqui, Juby Jacob-Nara, Jerome Msihid, Chien-Chia Chuang, Siddhesh Kamat, et al.
Pages: AB133 - AB133